Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Core Insights - The recent post-hoc analysis of the REDUCE-IT study indicates that icosapent ethyl (IPE) significantly reduces composite cardiovascular (CV) endpoint events by 34% among patients with very well-controlled low-density lipoprotein cholesterol (LDL-C) levels (<55 mg/dL) [1][4] - IPE is positioned as a complementary therapy to existing LDL-C lowering treatments, enhancing cardiovascular outcomes and potentially saving lives [1][2] Company Insights - Amarin Corporation emphasizes the efficacy and safety profile of VASCEPA (icosapent ethyl), advocating its use alongside standard care to mitigate cardiovascular disease risk, which remains the leading cause of death globally [1][2] - The company has a commitment to advancing treatment options for patients with persistent cardiovascular risk despite statin therapy, as evidenced by the incorporation of IPE into multiple global guidelines [2][4] Industry Insights - Elevated LDL-C is recognized as a major cardiovascular risk factor, with recent guidelines recommending LDL-C levels be lowered to <55 mg/dL for high-risk patients [1][2] - The cardiovascular disease landscape shows a pressing need for additional evidence-based therapies beyond standard treatments, particularly for patients with elevated triglycerides who remain at significant risk for cardiovascular events [2][11]